Literature DB >> 10559286

Splicing regulatory elements within tat exon 2 of human immunodeficiency virus type 1 (HIV-1) are characteristic of group M but not group O HIV-1 strains.

P S Bilodeau1, J K Domsic, C M Stoltzfus.   

Abstract

In the NL4-3 strain of human immunodeficiency virus type 1 (HIV-1), regulatory elements responsible for the relative efficiencies of alternative splicing at the tat, rev, and the env/nef 3' splice sites (A3 through A5) are contained within the region of tat exon 2 and its flanking sequences. Two elements affecting splicing of tat, rev, and env/nef mRNAs have been localized to this region. First, an exon splicing silencer (ESS2) in NL4-3, located approximately 70 nucleotides downstream from the 3' splice site used to generate tat mRNA, acts specifically to inhibit splicing at this splice site. Second, the A4b 3' splice site, which is the most downstream of the three rev 3' splice sites, also serves as an element inhibiting splicing at the env/nef 3' splice site A5. These elements are conserved in some but not all HIV-1 strains, and the effects of these sequence changes on splicing have been investigated in cell transfection and in vitro splicing assays. SF2, another clade B virus and member of the major (group M) viruses, has several sequence changes within ESS2 and uses a different rev 3' splice site. However, splicing is inhibited by the two elements similarly to NL4-3. As with the NL4-3 strain, the SF2 A4b AG dinucleotide overlaps an A5 branchpoint, and thus the inhibitory effect may result from competition of the same site for two different splicing factors. The sequence changes in ANT70C, a member of the highly divergent outlier (group O) viruses, are more extensive, and ESS2 activity in tat exon 2 is not present. Group O viruses also lack the rev 3' splice site A4b, which is conserved in all group M viruses. Mutagenesis of the most downstream rev 3' splice site of ANT70C does not increase splicing at A5, and all of the branchpoints are upstream of the two rev 3' splice sites. Thus, splicing regulatory elements in tat exon 2 which are characteristic of most group M HIV-1 strains are not present in group O HIV-1 strains.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10559286      PMCID: PMC113023     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  21 in total

1.  Modification of the megaprimer method of PCR mutagenesis: improved amplification of the final product.

Authors:  A Aiyar; J Leis
Journal:  Biotechniques       Date:  1993-03       Impact factor: 1.993

2.  Further evidence of the presence of genetically aberrant HIV-1 strains in Cameroon and Gabon.

Authors:  W Janssens; J N Nkengasong; L Heyndrickx; K Fransen; P M Ndumbe; E Delaporte; M Peeters; J L Perret; A Ndoumou; C Atende
Journal:  AIDS       Date:  1994-07       Impact factor: 4.177

3.  Biological importance and cooperativity of HIV-1 regulatory gene splice acceptors.

Authors:  N L Riggs; S J Little; D D Richman; J C Guatelli
Journal:  Virology       Date:  1994-07       Impact factor: 3.616

4.  Origin of HIV-1 in the chimpanzee Pan troglodytes troglodytes.

Authors:  F Gao; E Bailes; D L Robertson; Y Chen; C M Rodenburg; S F Michael; L B Cummins; L O Arthur; M Peeters; G M Shaw; P M Sharp; B H Hahn
Journal:  Nature       Date:  1999-02-04       Impact factor: 49.962

5.  Genomic cloning and complete sequence analysis of a highly divergent African human immunodeficiency virus isolate.

Authors:  M Vanden Haesevelde; J L Decourt; R J De Leys; B Vanderborght; G van der Groen; H van Heuverswijn; E Saman
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

6.  Presence of negative and positive cis-acting RNA splicing elements within and flanking the first tat coding exon of human immunodeficiency virus type 1.

Authors:  B A Amendt; D Hesslein; L J Chang; C M Stoltzfus
Journal:  Mol Cell Biol       Date:  1994-06       Impact factor: 4.272

7.  Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei.

Authors:  J D Dignam; R M Lebovitz; R G Roeder
Journal:  Nucleic Acids Res       Date:  1983-03-11       Impact factor: 16.971

8.  Scanning and competition between AGs are involved in 3' splice site selection in mammalian introns.

Authors:  C W Smith; T T Chu; B Nadal-Ginard
Journal:  Mol Cell Biol       Date:  1993-08       Impact factor: 4.272

9.  Alternative splicing of human immunodeficiency virus type 1 mRNA modulates viral protein expression, replication, and infectivity.

Authors:  D F Purcell; M A Martin
Journal:  J Virol       Date:  1993-11       Impact factor: 5.103

10.  Splicing variability in HIV type 1 revealed by quantitative RNA polymerase chain reaction.

Authors:  M Neumann; J Harrison; M Saltarelli; E Hadziyannis; V Erfle; B K Felber; G N Pavlakis
Journal:  AIDS Res Hum Retroviruses       Date:  1994-11       Impact factor: 2.205

View more
  14 in total

1.  Selective modification of alternative splicing by indole derivatives that target serine-arginine-rich protein splicing factors.

Authors:  Johann Soret; Nadia Bakkour; Sophie Maire; Sébastien Durand; Latifa Zekri; Mathieu Gabut; Weronika Fic; Gilles Divita; Christian Rivalle; Daniel Dauzonne; Chi Hung Nguyen; Philippe Jeanteur; Jamal Tazi
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-06       Impact factor: 11.205

2.  Molecular mechanisms in the dramatic enhancement of HIV-1 Tat transduction by cationic liposomes.

Authors:  Guan-Han Li; Wenxue Li; Russell J Mumper; Avindra Nath
Journal:  FASEB J       Date:  2012-03-23       Impact factor: 5.191

3.  Identification of new and unusual rev and nef transcripts expressed by an HIV type 1 primary isolate.

Authors:  Yolanda Vega; Elena Delgado; Cristina Carrera; Paloma Nebreda; Aurora Fernández-García; María Teresa Cuevas; Lucía Pérez-Álvarez; Michael M Thomson
Journal:  AIDS Res Hum Retroviruses       Date:  2013-05-08       Impact factor: 2.205

4.  Repair of a Rev-minus human immunodeficiency virus type 1 mutant by activation of a cryptic splice site.

Authors:  K Verhoef; P S Bilodeau; J L van Wamel; J Kjems; C M Stoltzfus; B Berkhout
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

5.  Conserved stem-loop structures in the HIV-1 RNA region containing the A3 3' splice site and its cis-regulatory element: possible involvement in RNA splicing.

Authors:  S Jacquenet; D Ropers; P S Bilodeau; L Damier; A Mougin; C M Stoltzfus; C Branlant
Journal:  Nucleic Acids Res       Date:  2001-01-15       Impact factor: 16.971

6.  RNA splicing at human immunodeficiency virus type 1 3' splice site A2 is regulated by binding of hnRNP A/B proteins to an exonic splicing silencer element.

Authors:  P S Bilodeau; J K Domsic; A Mayeda; A R Krainer; C M Stoltzfus
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

7.  PTAP motif duplication in the p6 Gag protein confers a replication advantage on HIV-1 subtype C.

Authors:  Shilpee Sharma; Prabhu S Arunachalam; Malini Menon; Viswanath Ragupathy; Ravi Vijaya Satya; Joshua Jebaraj; Shambhu Ganeshappa Aralaguppe; Chaitra Rao; Sreshtha Pal; Shanmugam Saravanan; Kailapuri G Murugavel; Pachamuthu Balakrishnan; Suniti Solomon; Indira Hewlett; Udaykumar Ranga
Journal:  J Biol Chem       Date:  2018-05-17       Impact factor: 5.157

Review 8.  Role of Tat protein in HIV neuropathogenesis.

Authors:  Wenxue Li; Guanhan Li; Joseph Steiner; Avindra Nath
Journal:  Neurotox Res       Date:  2009-03-21       Impact factor: 3.911

9.  Identification of new splice sites used for generation of rev transcripts in human immunodeficiency virus type 1 subtype C primary isolates.

Authors:  Elena Delgado; Cristina Carrera; Paloma Nebreda; Aurora Fernández-García; Milagros Pinilla; Valentina García; Lucía Pérez-Álvarez; Michael M Thomson
Journal:  PLoS One       Date:  2012-02-17       Impact factor: 3.240

10.  The word landscape of the non-coding segments of the Arabidopsis thaliana genome.

Authors:  Jens Lichtenberg; Alper Yilmaz; Joshua D Welch; Kyle Kurz; Xiaoyu Liang; Frank Drews; Klaus Ecker; Stephen S Lee; Matt Geisler; Erich Grotewold; Lonnie R Welch
Journal:  BMC Genomics       Date:  2009-10-08       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.